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ABSTRACT  
Importance: Antihyperglycaemic drugs can have different, often divergent, effects on 
cardiovascular risk and mortality.  
 
Objective: To conduct a systematic review and meta-analysis to determine the risk of 
cardiovascular events and all-cause mortality associated with sulfonylureas versus other 
antihyperglycaemic drugs. 
 
Data sources and study selection: A systematic review of Medline, Embase, Cochrane, 
and clinicaltrials.gov (Inception-December 2014) was conducted. Study selection 
occurred in duplicate. Eighty-two randomized clinical trials (RCTs) and 26 observational 
studies comparing sulfonylurea to placebo or other antihyperglycaemic drugs in patients 
with type 2 diabetes were included.  
 
Data extraction and synthesis: Data were extracted in duplicate for study, intervention, 
patient characteristics, and outcomes. Since RCT outcomes data were reported as binary 
data, but at different time points, a cloglog model was employed in the Bayesian 
framework to obtain comparative hazard ratios between interventions. For the analysis of 
observational data, conventional fixed-effect pairwise meta-analyses were employed to 
pool adjusted hazard ratios for each pair wise treatment comparison.  
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Main outcomes and measures: The following outcomes were of interest: all-cause 
mortality, cardiovascular-related mortality, acute myocardial infarction, and stroke.  
 
Results: Analyses of RCT data showed an increased risk of all-cause mortality and 
cardiovascular related mortality for sulfonylureas compared to all treatments combined 
(HR 1.26, 95% CI 1.10-1.44 and HR 1.46, 95% CI 1.21-1.77, respectively). These results 
were corroborated in the analyses of observational studies. The risk of myocardial 
infarction was significantly higher for sulfonylureas compared to DPP-4 inhibitors and 
SGLT-2 inhibitors (HR 2.54, 95% CI 1.14-6.57 and HR 41.80, 95% CI 1.64-360.4, 
respectively), but not in other classes of treatments. Observational studies confirmed an 
increased risk of myocardial infarction for sulfonylureas compared to all other treatments 
combined. The RCTs showed that the risk of stroke was significantly higher for 
sulfonylureas compared to DPP-4 inhibitors, GLP-1 agonists, TZDs, and insulin (HR 
9.40, 95% CI 3.27-41.9; HR 45.40, 95% CI 1.99-362.7; HR 1.75, 95% CI 1.20-2.69; and 
HR 1.46, 95% CI 1.01-2.14, respectively).  
 
Conclusions: This study shows that sulfonylurea therapy is generally associated with a 
higher risk of major cardiovascular disease-related events compared to other 
antihyperglycaemic drugs and this risk increases over time.  
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INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is known to increase the risk of cardiovascular (CV) 
disease, with a 3–5 fold increased risk of life-threatening events such as acute myocardial 
infarction (MI) and stroke.1,2 Recent trials have shown that glucose-lowering treatments 
may have different, sometimes divergent, effects on CV risk.3 Sulfonylureas (SUs) are 
among the most commonly used treatments for patients with T2DM, yet their long-term 
safety and their effects on CV outcomes remain uncertain and controversial.4 
 
The possibility that SUs increase CV risk is rooted in clinical and experimental evidence 
that extra-pancreatic KATP channels and SU receptors are expressed abundantly in 
cardiac myocytes (SUR2A) and vascular smooth muscle cells (SUR2B). Off-target 
KATP channel blockade in the heart and vascular smooth muscle cells may lead to 
adverse CV events.5 Animal and human studies have shown that SU binding to SUR2A 
and SUR2B receptors causes adverse effects on CV function, especially in the context of 
myocardial ischaemia.6,7 SUs act on the myocardial ATP-sensitive potassium channel, 
which can impair the ability of myocardiocytes to adapt to ischaemia, thus affecting 
cardiac function in patients with ischaemic heart disease.8 Furthermore, SUs may also 
have harmful, indirect effects on CV function, e.g. via hypoglycaemia-induced changes 
in QT-interval and arrhythmogenesis,9 pro-thrombotic effects and endothelial 
dysfunction.10,11  
 
There is no single published randomized clinical trial (RCT) that has examined the risk of 
CV events between SUs and a wide spectrum of commonly prescribed 
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antihyperglycaemic drugs. Several systematic reviews and meta-analyses have compared 
SUs with a variety of antihyperglycaemic drugs. However, findings of these studies are 
inconsistent; this is largely because of differences in study selection and statistical 
techniques used to analyze the data.12-19 The most recent meta-analysis on this topic was 
presented by Rados et al at the American Diabetes Association 2015 Scientific 
Sessions.19 These investigators generally concluded that SUs are not associated with 
increased mortality, with the exception of glipizide, which increased the risk for total and 
CV-related mortality. Another recent meta-analysis, by Monami et al,13 showed increased 
mortality and a higher risk of stroke with SUs. However, the only comparison where 
results were statistically significant was the increased odds of a CV event for patients on 
a SU in comparison to those on a DPP-4 inhibitor. Furthermore, a study by Simpson et al 
focused on the difference in risk between SUs, and found that gliclazide and glimepiride 
were associated with a lower risk of all-cause and CV-related mortality when compared 
with glibenclamide.20 
 
Using advanced meta-analytical techniques, the aim of this study was to assess the risk of 
CV-related outcomes associated with SUs versus other antihyperglycaemic drugs using 
data from RCTs and comparative observational studies. Analyses of survival data were 
performed separately for both RCT evidence and observational evidence to facilitate a 
multi-level inference approach.  
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METHODS 
Overview 
We conducted a systematic literature review to identify studies that compared SU 
monotherapy or a SU in combination with another antihyperglycaemic drug against 
placebo/no intervention or other antihyperglycaemic drugs. Data derived from the studies 
identified in the systematic literature review were used to compare the risk of CV events 
associated with the use of SUs and the other selected treatments.  
 
Eligibility criteria 
The eligibility criteria used to select studies in the systematic literature review are 
presented according to the PICOS (population, intervention, control, outcomes, study 
design) convention (eTable 1). In brief, RCTs and non-randomized comparative studies, 
including prospective or retrospective observational cohort studies and case-control 
studies, conducted among adult patients diagnosed with T2DM who were either treatment 
naïve or had prior exposure to antihyperglycaemic drugs were eligible for inclusion. 
Eligible interventions included SU monotherapy or a SU in combination with a biguanide 
or another antihyperglycaemic drug (i.e. biguanides, dipeptidyl peptidase protein-4 [DPP-
4] inhibitors, glucagon-like peptide-1 [GLP-1] agonists, sodium-glucose linked 
transporter-2 [SGLT-2] inhibitors, thiazolidinediones [TZDs], insulin). Eligible 
comparators included placebo/no intervention or other antihyperglycaemic drugs. 
Outcomes of interest included all-cause mortality, CV-related mortality, acute MI, and 
stroke.   
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Literature search 
A systematic search of the peer-reviewed literature was conducted in Medline, Embase, 
and Cochrane Register of Controlled Trials from inception to December 2014 (eTable 2 
presents the search strategy used). Additionally, clinicaltrials.gov was searched to 
identify potentially eligible RCTs with results that had not yet been published in a peer-
reviewed journal.  
 
Two investigators independently identified relevant abstracts and full-text publications 
based on the eligibility criteria. If any discrepancies occurred between the studies 
selected by the two investigators, a third investigator provided arbitration. For all the 
articles that were not published in English language, a separate search was conducted 
using the author names to see if a relevant publication in English exists. If not, non-
English publications were discarded.  
 
Data extraction 
Two reviewers working independently extracted data on study characteristics, 
interventions, patient characteristics at baseline, and outcomes for the study populations 
of interest for the eligible studies. If discrepancies occurred between the data extracted by 
the two reviewers, these differences were reconciled by involving a third reviewer. In the 
event that the third reviewer could not resolve a disagreement, the authors of the 
publication were contacted for clarification.  
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Data on all outcomes were extracted as intention-to-treat analyses, where all dropouts 
were assumed to be treatment failures, wherever trial reporting allowed this. For studies 
that reported “per-protocol” results only, these were extracted and used in the analyses. 
For observational studies, we focused on extracting adjusted estimates representing 
comparative effects through hazard ratios, odds ratios, or relative risks as intention-to-
treat and per-protocol issues were not relevant. 
 
Study quality 
For included RCTs, we assessed the validity of individual trials using the Risk of Bias 
instrument, endorsed by the Cochrane Collaboration.21 This instrument is used to 
evaluate six key domains: sequence generation; allocation concealment; blinding of 
participants, personnel, and outcome assessors; incomplete outcome data; selective 
outcome reporting; and other sources of bias. 
 
For observational studies, we used the Newcastle-Ottawa scale. Using the scale, each 
study is judged on eight items, categorized into three groups: the selection of the study 
groups; the comparability of the groups; and the ascertainment of either the exposure or 
outcome of interest for case-control or cohort studies respectively. Stars awarded for each 
quality item serve as a quick visual assessment. 
 
The same two reviewers extracting data conducted the quality assessment. If 
disagreements between the reviewers occurred, we resolved these by including a third 
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reviewer, and if necessary, contacting the authors of the publication for clarification. No 
studies were excluded on the basis of quality. 
 
Evidence synthesis 
Treatments were grouped according to drug class. First- and second-generation SUs were 
treated as one group. Other drug classes included biguanides, DPP-4 inhibitors, GLP-1 
agonists, SGLT-2 inhibitors, TZDs, and insulins. When biguanides were used as 
background therapy, the intervention therapy was analyzed as a monotherapy.  
 
For all four outcomes (all-cause mortality, CV-related mortality, acute MI, and stroke), 
meta-analysis was employed to establish comparative efficacy between SU versus other 
drug classes. The hazard ratio was employed as a primary effect measure (i.e. primary 
analysis) to evaluate comparative efficacy. Analyses were performed separately for RCT 
evidence and observational evidence to facilitate a multi-level inference approach. 
 
For the primary analysis of RCT data, a Bayesian hierarchical approach was employed in 
the framework of indirect treatment comparisons. The choice whether to use a fixed- or 
random-effects model was determined by comparing the values of the deviance 
information criterion for each model as well as assessing the heterogeneity variance 
provided in the random-effects model. Since RCT data were only available as binary 
data, but at differing time points, and since the effect measure of interest was the hazard 
ratio, a binomial model with a cloglog link function and a time offset (cloglog model) 
was employed in the Bayesian framework to obtain comparative hazard ratios between 
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interventions.22 For the primary analysis of observational data, conventional fixed-effect 
pairwise meta-analyses were employed to pool adjusted hazard ratios for each pair-wise 
treatment comparison.  
 
Since the outcomes typically only occurred once, we assumed that adjusted relative risks 
from observational studies could be considered similar to adjusted hazard ratios, and thus 
pooled the two where relevant. From the cloglog model of RCT data, we further 
estimated the survival functions for each of the interventions of interest. From these 
survival functions, we calculated the absolute difference in risk of each outcome between 
SU and each of the other interventions. We additionally calculated the same absolute 
differences in risk based on the observational data, using the estimated survival function 
for SU and the pooled (observational) hazard ratios to produce survival functions for the 
other interventions.  
 
We produced two types of forest plots to graphically display the results. The first 
compared the study specific estimates provided in each study and the second compared 
the relative efficacies between treatments as estimated in the analysis. In traditional meta-
analysis, forest plots are used to present the results from individual studies and the 
synthesized result from the analysis, providing a visual assessment of the statistical 
heterogeneity. Statistical heterogeneity is caused by differences in factors that influence 
the outcome or the intervention, such as prognostic factors. As explained above, our 
analyses account for an important effect modifier, namely time. Longer follow-up periods 
lead to higher probabilities of an event occurring. 
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Since rosiglitazone has been suspended in many settings due to concerns of CV safety,3 a 
sensitivity analysis was conducted excluding this treatment from the TZD class. 
 
All Bayesian analyses were performed in WinBUGS v3.1.4, and all conventional meta-
analyses and figures were performed and produced using R v3.1.2. 
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RESULTS 
Included studies 
The systematic literature review yielded 14,841 abstracts for screening. Subsequently 830 
full-text articles were reviewed, of which 722 were excluded: 64 due to an ineligible 
population, 93 due to an ineligible intervention, 36 due to an ineligible comparison, 393 
due to lack of outcomes of interest, 126 due to an ineligible study design, and 10 for other 
(e.g. study not in English language). Of these, 108 studies were included (82 RCTs and 
26 observational studies). The flow of study selection is presented in eFigure 1, and the 
summary of baseline characteristics and quality of included studies is presented in eTable 
3 – eTable 8.  
 
All-cause mortality 
The results of the analysis of all-cause mortality for the RCT and observational evidence 
are detailed in Table 1 and Figure 1.A. Additionally, eFigure 2 presents the forest plot 
for showing individual study results. When considering RCT evidence, the results 
indicate an increased risk of all-cause mortality for SUs in comparison to all other active 
treatments (HR 1.26, 95% CI 1.10-1.44). Four of these comparisons were statistically 
significant: SUs versus biguanides (HR 1.37, 95% CI 1.03-1.84), DPP-4 inhibitors (HR 
2.03, 95% CI 1.22-3.58), TZDs (HR 1.54, 95% CI 1.14-2.10), and insulins (HR 1.21, 
95% CI 1.01-1.45). When compared to no active treatment, SUs demonstrated an 
increase in risk, however this was not statistically significant.  
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Where observational evidence was available, results trended in the same direction as the 
RCT evidence, with the exception of SUs versus insulins. Each comparison using 
observational evidence was statistically significant.  
 
Cardiovascular-related mortality 
The results of the analyses of the risk of CV-related mortality are presented in Table 1 
and Figure 1.B. In addition, eFigure 3 provides the forest plot showing individual study 
results. Analyses of RCT evidence indicated that there is an increased risk of CV related 
mortality for SUs in comparison to all other active treatments (HR 1.46, 95% CI 1.21-
1.77). These results were statistically significant for SUs versus DPP-4 inhibitors (HR 
4.42, 95% CI 1.92-13.0), GLP-1 agonists (HR 45.4, 95% CI 2.07-362.8), SGLT-2 
inhibitors (HR 42.6, 95% CI 1.71-359.1), TZDs (HR 3.05, 95% CI 1.79-5.54), and 
insulins (HR 1.30, 95% CI 1.02-1.66). When compared to no active treatment, SUs 
demonstrated an increase in risk, however this was not statistically significant.  
 
Observational data were only available for the SU versus no treatment and insulin 
comparisons. Similar to the RCT evidence, SUs tended to have a greater risk of CV-
related mortality with the observational evidence, however this was not statistically 
significant. When considering SUs versus insulins with observational evidence, the risk 
of CV-related mortality was in the opposite direction of the RCT data, although this 
estimate was not statistically significant.  
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Acute myocardial infarction 
The results of the analyses of the risk of acute MI are provided in Table 1 and Figure 
1.C. Additionally, eFigure 4 presents the forest plot showing the individual study results. 
The analyses of RCT evidence demonstrated that SUs increased the risk of acute MI in 
comparison to all other active treatments, with the exception of insulins. These results 
were statistically significant for SUs versus DPP-4 inhibitors (HR 2.54, 95% CI 1.14-
6.57) and SGLT-2 inhibitors (HR 41.8, 95% CI 1.64-360.4). Although results indicate a 
decrease in the risk of acute MI for SUs compared to no active treatment, this comparison 
was not statistically significant.  
 
Observational data were also available for the comparison of SUs versus TZDs. The 
increased risk of acute MI with the use of SUs compared to TZDs was statistically 
significant when considering observational evidence.  
 
Stroke 
The results of the analyses of the risk of stroke are provided in Table 1 and Figure 1.D. 
In addition, eFigure 5 presents the forest plot showing the individual study results.  The 
analysis of RCT evidence indicated that SUs increased the risk of stroke relative to all 
other active treatments. These results were statistically significant for the comparisons of 
SUs versus DPP-4 inhibitors (HR 9.40, 95% CI 3.27-41.9), GLP-1 inhibitors (HR 45.4, 
95% CI 1.99-362.7), TZDs (HR 1.75, 95% CI 1.20-2.69), and insulins (HR 1.46, 95% CI 
1.01-2.14). When SUs were compared to no active treatment, there was an increase in 
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risk, however this estimate was not statistically significant. No observational data were 
available for this outcome. 
 
Sensitivity analysis 
When excluding rosiglitazone in the comparison of SUs versus TZDs, the risk of all-
cause mortality (HR 3.58, 95% CI 1.87-7.87), CV-related mortality (HR 3.62, 95% CI 
1.88-7.96), acute MI (HR 1.44, 95% CI 0.87-2.50), and stroke (HR 2.07, 95% CI 1.12-
4.19) increased with the RCT evidence base. However, when removing rosiglitazone in 
the analyses of the observational evidence base, the results were comparable.   
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DISCUSSION 
This study is the most comprehensive review of RCTs and observational studies to 
compare CV-related outcomes and all-cause mortality among patients with T2DM treated 
with a SU versus other antihyperglycaemic agents, including insulin and the newer drugs 
such as SGLT-2 inhibitors. Results for the RCT pooled hazard ratios indicate that 
treatment with a SU was associated with a significantly higher risk of all-cause mortality 
and CV-related mortality when compared to all other treatments. The differences ranged 
from a doubling of mortality risk versus a DPP-4 inhibitor to more modest differences 
relative to insulin or metformin treatment. Some of the confidence intervals were wide, 
but the significant results all trended in the same direction. All-cause mortality and CV-
related mortality had the greatest number of statistically significant results and the 
analysis of observational studies generally supported the results from RCTs.  
 
There were two major discrepancies between the observational and RCT analyses. First, 
the comparison of SU and insulin for the outcome of CV-related mortality; RCT results 
showed a significant increase in risk for SUs, while observational results showed a 
decrease in risk. The observational data were, however, sparse (only two trials available) 
which may explain the lack of statistical significance. The second was the comparison of 
SU and insulin for the outcome of all-cause mortality; the RCT results showed a 
significant increase in risk while the observational evidence suggested a significant 
decrease. However, the observational data exhibited significant heterogeneity as 
identified with the Cochrane-Q (p-value < 0.001), which may explain this discrepancy.  
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Several systematic reviews have addressed similar topics concerning SU therapy.9,12-
15,18,20,23,24 However, these studies had important methodological limitations, in particular 
grouping treatments with diverse safety profiles, imprecise study inclusion criteria, non-
systematic searches, and important analytical limitations. Four of the studies reported 
similar results to ours for all-cause mortality and CV-related mortality.12,15,18,24 Two of 
these studies only included subsets of SUs.9,23 Two of these reviews were associated with 
methodological limitations, such as incorrect inclusions, inconsistent reporting, and lack 
of a rigorous search strategy.13,14 Finally, one recent review assessed CV outcomes, 
however this meta-analysis only included SUs and aimed to report on differences within 
this treatment class.20    
 
SU-mediated inhibition of ischaemic preconditioning and hypoglycaemia-related 
arrhythmogenesis are the principal mechanisms cited to support the biological plausibility 
of a harmful link between SUs and CV disease.  However, very few RCTs with SUs have 
included CV endpoints and the trials to date have been relatively small and of short 
duration. Future trials, e.g. the TOSCA.IT25 and CAROLINA,26 may provide important 
information but not for several years.  Furthermore, the large studies that have been 
performed in patients with type 2 diabetes treated with SUs, e.g. UKPDS27 and 
ADVANCE,28 are of limited value since these trials evaluated the effects of glycaemic 
control rather than the effects of specific antihyperglycaemic agents.  Thus, in the 
absence of conclusive RCT data, the present meta-analysis offers the most 
comprehensive overview of SU trials using Bayesian techniques to quantify relative 
differences in major CV outcomes and all-cause mortality versus placebo (or no 
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treatment) and other classes of antihyperglycaemic drugs, including insulin therapy and 
the SGLT-2 inhibitors. Our analysis includes RCTs and observational studies, and 
overcomes many of the limitations of earlier analyses. 
 
The current analysis also has some limitations. First, the number of analyses conducted 
may have introduced multiplicity, i.e. a type one error (false positive) may have occurred 
in a comparison estimate. Second, the minimal amount of data in some analyses did not 
allow for robust effect estimates. For instance, low event counts in some comparisons 
(i.e. SU versus GLP-1 for CV-related mortality and stroke, and SU versus SGLT-2 for 
CV-related mortality and acute MI) resulted in wide confidence intervals and potentially 
misleading large risk differences. Third, our analyses focused on class effects to ensure 
sufficient sample sizes to detect differences; however, it should be recognized that 
individual SU treatments may differ in terms of mortality risk.20 Finally, there are 
inherent flaws in meta-analyses, which rely on high-quality study data. The current study 
used a rigorous search and extraction method to ensure high quality evidence was 
integrated appropriately. Risk of bias assessments were performed for both RCTs and 
observational studies to summarize study quality. 
 
Our findings generally indicated a higher risk of cardiovascular-related events associated 
with sulfonylureas compared to other antihyperglycaemic drugs. This risk increased over 
time, and it was confirmed in analysis of both clinical trial and observational studies. 
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Figure Titles and Legends 
 
Figure 1.A: Forest plot presenting hazard ratio estimates of all-cause mortality for 
sulfonylureas versus other antihyperglycemic drugs 
 
Figure 1.B: Forest plot presenting hazard ratio estimates of cardiovascular-related 
mortality for sulfonylureas versus other antihyperglycemic drugs 
 
Figure 1.C: Forest plot presenting hazard ratio estimates of acute myocardial infarction 
for sulfonylureas versus other antihyperglycemic drugs 
 
Figure 1.D: Forest plot presenting hazard ratio estimates of stroke for sulfonylureas 
versus other antihyperglycemic drugs 
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Table 1: Difference between sulfonylureas and other treatments for cardiovascular-related 
and mortality outcomes 
 RCT Observational 
Sulfonylurea vs HR (95% CI) HR (95% CI) I2 % (95% CI) 
All-cause mortality 
No active treatment/ 
placebo 
1.07 (0.90-1.28) 1.13 (1.07-1.19) 63.5 (14.2-79.3)a 
Biguanide 1.37 (1.03-1.84) 1.57 (1.48-1.66) 0.00 (0.00-64.1) 
DPP-4 inhibitor 2.03 (1.22-3.58) 1.58 (1.36-1.83) 0.00 (0.00-72.9) 
GLP-1 agonist 1.85 (0.80-5.19) - - 
SGLT-2 inhibitor - - - 
Thiazolidinedione 1.54 (1.14-2.10) 1.50 (1.32-1.71) 96.6 (93.9-97.8)b 
Insulin 1.21 (1.01-1.45) 0.82 (0.77-0.89) 92.4 (86.7-95.0)b 
Combined 1.26 (1.10-1.44) 1.22 (1.18-1.26) 92.4 (90.6-93.7)b 
Cardiovascular-related mortality 
No active treatment/ 
placebo 
1.25 (0.98-1.62) 1.16 (0.93-1.44) 73.9 (0.00-88.6)a 
Biguanide 1.38 (0.90-2.16) - - 
DPP-4 inhibitor 4.42 (1.92-13.0) - - 
GLP-1 agonist 45.4 (2.07-362.8) - - 
SGLT-2 inhibitor 42.6 (1.71-359.1) - - 
Thiazolidinedione 3.05 (1.79-5.54) - - 
Insulin 1.30 (1.02-1.66) 0.80 (0.52-1.24) - 
Combined 1.46 (1.21-1.77) 1.01 (0.89-1.14) 80.8 (58.6-88.6)b 
Acute myocardial infarction 
No active treatment/ 
placebo 
0.86 (0.70-1.06) - - 
Biguanide 1.21 (0.78-1.99) - - 
DPP-4 inhibitor 2.54 (1.14-6.57) - - 
GLP-1 agonist 1.49 (0.45-5.41) - - 
SGLT-2 inhibitor 41.8 (1.64-360.4) - - 
Thiazolidinedione 1.13 (0.83-1.59) 1.41 (1.23-1.62) 36.7 (0.00-78.3) 
Insulin 0.96 (0.78-1.18) - - 
Combined 0.92 (0.78-1.08) 1.34 (1.25-1.44) 16.5 (0.00-67.1) 
Stroke 
No active treatment/ 
placebo 
1.26 (0.88-1.81) - - 
Biguanide 1.40 (0.92-2.22) - - 
DPP-4 inhibitor 9.40 (3.27-41.9) - - 
GLP-1 agonist 45.4 (1.99-362.7) - - 
SGLT-2 inhibitor - - - 
Thiazolidinedione 1.75 (1.20-2.69) - - 
Insulin 1.46 (1.01-2.14) - - 
Combined 1.09 (0.86-1.39) - - 
Note: Bold text indicates statistical significance (95% confidence interval does not include 1.00); Pooled hazard 
ratios for RCTs were obtained by cloglog analysis; Random effect estimates were equivalent to fixed effect 
estimates for observational studies; Data reported is or the > 1 year time point; – not applicable due to lack of trial 
data; a - p-value < 0.01; b - p-value < 0.001  
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Figure 1.A: Forest plot presenting hazard ratio estimates of all-cause mortality for 
sulfonylureas versus other antihyperglycemic drugs 
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Figure 1.B: Forest plot presenting hazard ratio estimates of cardiovascular-related 
mortality for sulfonylureas versus other antihyperglycemic drugs 
  
 27 
Figure 1.C: Forest plot presenting hazard ratio estimates of acute myocardial 
infarction for sulfonylureas versus other antihyperglycemic drugs 
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Figure 1.D: Forest plot presenting hazard ratio estimates of stroke for sulfonylureas 
versus other antihyperglycemic drugs 
 
 
 
